Jefferies raised the firm’s price target on HealthEquity to $95 from $79 and keeps a Buy rating on the shares. The firm hosted HealthEquity CEO Jon Kessler, CFO Jim Lucania and IR lead Richard Putnam for meetings last week and came away with increased confidence in the long-term trajectory of the business, the analyst tells investors. Following the firm’s meetings, its near-term concern on rate cuts is diminished, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- Navigating Uncertainty: Healthequity Inc. Grapples with HSA Asset Volatility and Revenue Risks
- HealthEquity price target raised to $95 from $85 at KeyBanc
- HealthEquity price target raised to $110 from $100 at BTIG
- HealthEquity price target raised to $92 from $90 at RBC Capital
- HealthEquity price target raised to $97 from $93 at BofA
